News

Kaia COPD app approved in Germany and covered by insurance

Kaia Health’s smartphone app, designed to help people with chronic obstructive pulmonary disease (COPD) manage their breathing symptoms at home, can now be prescribed by medical providers in Germany and is covered by statutory health insurance in that country, the company announced. The app, called Kaia COPD, offers…

Hospital admission rates for COPD, asthma increase by 59% in UK

Hospital admission rates for patients with chronic obstructive pulmonary disease (COPD) and asthma increased by 59.1% in England and Wales between 1999 and 2020, a 21-year follow-up study reported. COPD accompanied by acute lower respiratory infection accounted for 38.7% of hospital admissions, and more than half of admitted patients…

Remote monitoring program may help reduce hospital readmissions

Biofourmis and Beacon Health System have partnered for an in-home monitoring program specifically meant for patients with complex chronic diseases, including chronic obstructive pulmonary disease (COPD), during their post-discharge period. Patient-reported data will be automatically collected, analyzed, and presented in a continuously updated dashboard visible to clinicians.

CPAP Use May Lower COPD Flare Risk in Patients With Sleep Apnea

People with chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) may experience fewer acute disease exacerbations if they regularly use noninvasive ventilation at night, a small study in Greece reported. “Good” nighttime use of continuous positive airway pressure (CPAP), a type of noninvasive ventilation, also aided lung…

Inflammatory Markers in Blood May Help ID COPD Outcomes Risk

Measuring inflammatory markers during routine blood tests in people with chronic obstructive pulmonary disease (COPD) could acute exacerbations at risk of experiencing worse outcomes, according to a small literature review study. Specifically, the researchers suggest measuring the neutrophil-to-lymphocyte ratio (NLR) — an indicator of systemic or body-wide inflammation. The…

Educating About Endobronchial Valves Is Aim of Collaboration

Pulmonx and the American Lung Association have partnered to educate patients and healthcare providers about treatment options, including endobronchial valves that can help people breathe easier who have severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Led by the American Lung Association, the Treating Severe COPD…

AstraZeneca Acquires Global Rights to C4XD’s NRF2 Activator Program

AstraZeneca has acquired the exclusive rights to develop and commercialize C4X Discovery’s oral NRF2 activator for treating chronic obstructive pulmonary disease (COPD) and other inflammatory and respiratory diseases. The activator program aims to harness the antioxidant and anti-inflammatory properties of NRF2 in these conditions, although COPD will be…

Japan Approves Zephyr Valve for Severe Emphysema

Pulmonx has won the green light in Japan to market its Zephyr Endobronchial Valve, a bronchoscope-placed device designed to help people breathe easier who have severe emphysema, a form of chronic obstructive pulmonary disease (COPD). With the OK from the Japanese Ministry of Health, Labour and Welfare…